Abstract
Spinocerebellar ataxia 27B (SCA27B) is a common autosomal dominant ataxia caused by an intronic GAA•TTC repeat expansion in FGF14. Neuropathological studies have shown that neuronal loss is largely restricted to the cerebellum. Although the repeat locus is highly unstable during intergenerational transmission, it remains unknown whether it exhibits cerebral mosaicism and progressive instability throughout life. We conducted an analysis of the FGF14 GAA•TTC repeat somatic instability across 156 serial blood samples from 69 individuals, fibroblasts, induced pluripotent stem cells, and post-mortem brain tissues from six controls and six patients with SCA27B, alongside methylation profiling using targeted long-read sequencing. Peripheral tissues exhibited minimal somatic instability, which did not significantly change over periods of more than 20 years. In post-mortem brains, the GAA•TTC repeat was remarkably stable across all regions, except in the cerebellar hemispheres and vermis. The levels of somatic expansion in the cerebellar hemispheres and vermis were, on average, 3.15 and 2.72 times greater relative to other examined brain regions, respectively. Additionally, levels of somatic expansion in the brain increased with repeat length and tissue expression of FGF14. We found no significant difference in methylation of wild-type and expanded FGF14 alleles in post-mortem cerebellar hemispheres between patients and controls. In conclusion, our study revealed that the FGF14 GAA•TTC repeat exhibits a cerebellar-specific expansion bias, which may explain the pure and late-onset cerebellar involvement in SCA27B.
Competing Interest Statement
DP reports no disclosures. JLM reports no disclosures. SB reports no disclosures. MCD reports no disclosures. MJD reports no disclosures. CSD reports no disclosures. DG reports no disclosures. GS reports no disclosures. CA reports no disclosures. JMH reports no disclosures. BJG reports no disclosures. VC reports no disclosures. PUL reports no disclosures. MS reports no disclosures. CY reports no disclosures. HL reports no disclosures. SKN reports no disclosures. GMR reports no disclosures. ZJ reports no disclosures. KP reports no disclosures. SA reports no disclosures. AN reports no disclosures. KU reports no disclosures. MR reports no disclosures. CB reports no disclosures. GR reports no disclosures. MAS reports no disclosures. JSN reports no disclosures. HH reports no disclosures. IWD manages a fee-for-service sequencing facility at the Garvan Institute of Medical Research that is a customer of Oxford Nanopore Technologies but has no further financial relationship. IWD has previously received travel and accommodation expenses to speak at Oxford Nanopore Technologies conferences. MN received consultancy honoraria from Reata Pharmaceuticals unrelated to this work. AB reports no disclosures. LMP received consultancy honoraria from Biogen unrelated to this work. DS reports no disclosures. SZ has received consultancy honoraria from Neurogene, Aeglea BioTherapeutics, Applied Therapeutics, and is an unpaid officer of the TGP foundation, all unrelated to the present manuscript. AD serves as an advisor at Critical Path Ataxia Therapeutics Consortium and her Institution (Paris Brain Institute) receives consulting fees on her behalf from Biogen, Huntix, UCB, as well as research grants from the NIH, ANR and holds partly a Patent B 06291873.5 on "Anaplerotic therapy of Huntington disease and other polyglutamine diseases". BB reports no disclosures.
Funding Statement
This work was supported by the Canadian Institutes of Health Research (grant 189963 to BB), the Fondation Groupe Monaco (to BB), and the NIH National Institutes of Neurological Disorders and Stroke (grant 2R01NS072248-11A1 to SZ). VC was supported by the Association of British Neurologists Academic Clinical Training Research Fellowship (grant ABN 540868) and the Guarantors of Brain (grant 565908). VC and HH received grants from the MSA Trust, MSA Coalition, MANX MSA, King Baudouin Foundation, the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre, Michael J Fox Foundation (MJFF), Fidelity Trust, Rosetrees Trust, Ataxia UK, Alzheimer's Research UK (ARUK), NIH NeuroBioBank, and MRC Brainbank Network. HH is supported by the Wellcome Trust, the UK Medical Research Council (MRC), and by the UCLH/UCL Biomedical Research Centre. SA is supported by the NIDA (grant DP1DA056018). AN is supported by the Intramural Research Program of the NIH funded in part with federal funds from the NCI under contract HHSN261201500003. GR is supported by an EL2 Investigator Grant (APP2007769) from the Australian National Health and Medica Research Council (NHMRC). IWD holds a fellowship from the Australian Medical Research Future Fund (MRFF, 1173594). MN and JSN are supported by Friedreich's Ataxia Research Alliance and NIH National Institutes of Neurological Disorders and Stroke (grant NS081366). DP holds a Fellowship award from the Canadian Institutes of Health Research and JLM holds a fellowship from the Fondation pour la Recherche Médicale (grant 13338). The funders had no role in the conduct of this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committees of the Montreal Neurological Hospital, Montreal (MPE-CUSM-15-915), the Centre Hospitalier de l'Université de Montréal, Montreal (ND02.045), the Dr. Josep Trueta University Hospital, Girona (2022.120), the Hôpital Pitié-Salpêtrière, Paris (SPATAX RBM 01-29 and RBM 03-48, BIOMOV NCT05034172), and the University College London Hospitals, London (04/N034) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
